(Reuters) – Alphabet Inc’s life sciences division Verily explained on Friday that it was placing on hold a single of its oldest and optimum-profile initiatives, a smart get hold of lens built to help observe sugar stages.
The undertaking, started off in 2014, aimed to assist diabetics much better manage their blood sugar degrees by embedding sensors on a call lens to watch the glucose stages in their tears.
In a blog site update, Verily cited below insufficient consistency in the correlation amongst tear glucose and blood glucose concentrations to assistance the requirements of a healthcare product.
Verily, which was previously section of the tech firm’s Google X investigation and improvement unit, had partnered with Novartis’ eye-care division, Alcon, to build the lens.
Alcon said in its own assertion that the conclusion to pause the job was built collectively with Verily.
The providers stated they would continue on to get the job done on two other ‘Smart Lens’ projects – a single for presbyopia, or much-sightedness, and a further intended to strengthen sight following cataract operation.
Verily received an $800 million investment from Singapore state trader Temasek final calendar year.
Reporting by Munsif Vengattil in Bengaluru and Paresh Dave in San Francisco Modifying by Maju Samuel and Rosalba O’Brien